Although the underlying mechanisms of these activities have not yet been defined, detailed pharmacological analyses indicate that the clinical effects result from the thalidomide molecule itself and not from any of its metabolites.
Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.
Results from in vitro and in vivo studies demonstrate that thalidomide inhibits the production of tumor necrosis factor–alpha ( TNF-alpha ) in monocytes, ostensibly by accelerating the degradation of TNF-alpha ribonucleic acid (RNA) transcripts. Other studies suggest that thalidomide may induce the down-regulation of integrin receptors and other surface adhesion proteins, reduce IgM production. alter CD4/CD8 T-cell ratios, and/or inhibit angiogenesis. However, lymphocyte proliferation does not appear to be affected by thalidomide.
Scheda completa Toxnet
Scheda completa Micromedex
Talidomide scheda tecnica